U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT06712927) titled 'Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases' on Nov. 27.
Brief Summary: This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Melanoma
Brain Metastases
Intervention:
DRUG: Ipilimumab
1 mg/kg of Ipilimumab will be administered via IV every 8 weeks. Participants will be assigned to Cohort A or B as per eligibility criteria. No randomization or blinding will occur
DRUG: Niv...